Pulmatrix Inc (PULM) gains 3.84% for July 21

Equities Staff  |

Pulmatrix Inc (NASDAQ: PULM) shares gained 3.84%, or $0.034 per share, to close Wednesday at $0.92. After opening the day at $0.90, shares of Pulmatrix fluctuated between $0.94 and $0.90. 263,397 shares traded hands a decrease from their 30 day average of 430,196. Wednesday's activity brought Pulmatrix’s market cap to $51,749,137.

Pulmatrix is headquartered in Lexington, Massachusetts..

About Pulmatrix Inc

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for serious lung diseases such as allergic bronchopulmonary aspergillosis ('ABPA') and lung cancer, as well as neurologic disorders such as acute migraine. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

Visit Pulmatrix Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Pulmatrix Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Pulmatrix Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content